Manufacturer NovoNordisk

XULTOPHY (IDegLira)

This is a combination of Insulin Degludec and Liraglutide (Victoza) 

Used for: treatment of T2DM alone, or in combination with oral therapies when these alone, and/or with basal insulin and/or GLP-1 analogue fail to provide adequate glycemic control. Before use, any GLP-1 analogues or DPP-4 inhibitors should be stopped. There is an increased risk of heart failure when used with pioglitazone.

Dose: see the video. Maximum daily dose  is 50 dose steps.

Side Effects:

Very common: hypoglycaemia. Common: vomiting, bloating , diarrhoea, abdominal pain, abdominal distension, constipation, headache, dizziness, fatigue, gastroesophageal reflux, rash, injection site reactions.

Renal impairment: Not recommended if Cr clearance is < 30ml/min.

Pregnancy: Stop before pregnancy, do not use during pregnancy.

Allergy advice: Does NOT contain meta-Cresol.

Contraindications: Allergy to any of the ingredients. In addition to this, in the US, also a past medical history or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Hyperplasia Type 2 (MEN 2). If a patient develops pancreatitis while taking this medication, do not restart the medication after the episode of pancreatitis.